The first FDA-approved application of LBNP for the RNAi-related therapy is patisiran, which is an LNP-based siRNA drug used for the treatment of polyneuropathy in people with hereditary transthyretin-mediated amyloidosis (ATTRm), which is a lethal disease caused by the mutation of transthyretin (TTR) gene expression [242]. This evidence concerns the gene TTR and polyneuropathy.